PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
June 1, 2024Journal of Clinical Oncology

Assessment of health-related quality of life (HRQoL) in triple-class–exposed patients with relapsed or refractory multiple myeloma (RRMM) treated with linvoseltamab in the LINKER-MM1 trial.

View Full Paper
Ask AI
Bookmark
Share

Authors

JHJames E. HoffmanNBNaresh BummaJRJoshua Richter

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hoffman et al. (2024) studied this question.

synapsesocial.com/papers/68e66f03b6db6435875fa210https://doi.org/10.1200/jco.2024.42.16_suppl.e23185
View Full Paper
Ask AI
Bookmark
Share